NHS to Offer AbbVie's Elahere for Ovarian Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: seekingalpha
- New Therapy Introduction: The NHS will start offering AbbVie's ovarian cancer therapy Elahere following a recommendation from NICE, expected to benefit up to 400 patients annually, marking the first new treatment for platinum-resistant ovarian cancer in over two decades.
- Defined Indication: This antibody-drug conjugate will be available for ovarian cancer patients whose disease has progressed after standard platinum-based chemotherapy, particularly those with tumors expressing folate receptor alpha, thus providing a new treatment option for a specific patient group.
- Commercial Agreement Reached: The launch of Elahere will be based on a confidential commercial deal between AbbVie and the NHS, as last year AbbVie indicated it could not launch the drug for NHS patients without securing a reasonable price from NICE, highlighting the importance of drug pricing negotiations.
- Policy Adjustment Impact: NICE has revised its drug value appraisal criteria, committing to increase drug spending in exchange for zero tariffs on British pharmaceuticals and MedTech products as part of a U.K.-U.S. trade deal, paving the way for AbbVie's drug market entry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 224.940
Low
223.00
Averages
252.00
High
289.00
Current: 224.940
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NHS to Offer AbbVie's Elahere for Ovarian Cancer Treatment
- New Therapy Introduction: The NHS will start offering AbbVie's ovarian cancer therapy Elahere following a recommendation from NICE, expected to benefit up to 400 patients annually, marking the first new treatment for platinum-resistant ovarian cancer in over two decades.
- Defined Indication: This antibody-drug conjugate will be available for ovarian cancer patients whose disease has progressed after standard platinum-based chemotherapy, particularly those with tumors expressing folate receptor alpha, thus providing a new treatment option for a specific patient group.
- Commercial Agreement Reached: The launch of Elahere will be based on a confidential commercial deal between AbbVie and the NHS, as last year AbbVie indicated it could not launch the drug for NHS patients without securing a reasonable price from NICE, highlighting the importance of drug pricing negotiations.
- Policy Adjustment Impact: NICE has revised its drug value appraisal criteria, committing to increase drug spending in exchange for zero tariffs on British pharmaceuticals and MedTech products as part of a U.K.-U.S. trade deal, paving the way for AbbVie's drug market entry.
See More
Analysis of Healthcare Stock Recovery Opportunities
- AbbVie Outlook: AbbVie's stock has declined 6% this year, yet its immunology drugs Skyrizi and Rinvoq are exceeding expectations, driving revenue and earnings growth, with several new medicines expected to launch over the next five years, enhancing its market competitiveness.
- New Drug Potential: AbbVie's investigational drugs Tavapadon and ABBV-295 are poised for future approvals, with Tavapadon potentially exceeding $1 billion in annual sales, while ABBV-295 offers significant differentiation in the weight management market, bolstering long-term growth prospects.
- Vertex Drug Performance: Vertex Pharmaceuticals' stock is down 5%, but its monopoly in cystic fibrosis will continue to generate stable revenue, with projected new drug revenues reaching $500 million this year, indicating strong potential in product development.
- Clinical Progress and Market Opportunities: Vertex's povetacicept is undergoing accelerated approval, expected by November, which could provide new growth momentum, further solidifying its position in the biopharmaceutical market.
See More
Investment Opportunities in Healthcare Stocks
- AbbVie Stock Performance: AbbVie's stock has declined 6% this year, yet its immunology products Skyrizi and Rinvoq are exceeding expectations, driving revenue and earnings growth, with several new drugs expected to launch in the next five years, particularly Tavapadon for Parkinson's disease, which could exceed $1 billion in annual sales.
- ABBV-295 Potential: AbbVie's investigational weight loss therapy ABBV-295 has shown promising results in clinical trials, and with the growing demand for chronic weight management drugs, it is expected to provide a new revenue stream, further enhancing the competitiveness of its product portfolio.
- Vertex Drug Prospects: Despite Vertex Pharmaceuticals' stock dropping 5%, its cystic fibrosis drugs can still sustain stable revenue, with new drugs Journavx and Casgevy expected to generate at least $500 million in revenue this year, showcasing the company's potential in drug development.
- Clinical Progress and Market Positioning: Vertex is advancing its application for accelerated approval of povetacicept, which, if approved, will become a significant growth driver, and combined with its market performance over the next decade, Vertex remains a top stock to invest in.
See More
Analysis and Comparison of Top Dividend ETFs
- Overview of VYM: The Vanguard High Dividend Yield ETF holds 608 stocks and has delivered an annualized return of 11.5% over the past five years; although it has underperformed the S&P 500 during this period, its diversified portfolio offers lower volatility and better risk management for investors.
- Characteristics of HDV: The iShares Core High Dividend ETF contains only 74 stocks and has achieved an annualized return of 11.4% over the past five years; while its dividend yield of 2.88% is higher than VYM's, its higher concentration may expose investors to greater market risks.
- Investment Strategy Considerations: Despite both ETFs ranking among the top dividend investments, their inability to outperform the S&P 500 over the past five years suggests that investors should consider options with higher growth potential, especially for those seeking capital appreciation.
- Diversification Advantage: VYM's diversified portfolio allows it to effectively mitigate risks in a market environment where technology stocks are heavily weighted, making it suitable for dividend investors looking to avoid concentrated investments in specific sectors.
See More
Wall Street Predicts 14% Upside for S&P 500
- S&P 500 Target Price: Wall Street anticipates a 14% increase in the S&P 500 over the next year, with a target price of 8,698, up from the current level of 7,615, reflecting optimism about economic recovery.
- Healthcare Sector Outlook: Analysts predict that earnings growth in the healthcare sector will slow to 3% by 2026, although it is expected to accelerate to 19% in 2027; however, the current valuation of 27 times earnings may deter investors due to perceived overvaluation.
- Communication Services ETF Performance: The Vanguard Communication Services ETF has returned 152% over the past decade (annualized at 9.6%), with major holdings like Alphabet and Meta, and is projected to see earnings growth of 28% in 2026, indicating strong growth potential.
- Investment Recommendations: Despite the positive outlook for healthcare and communication services, analysts suggest maintaining a larger allocation in S&P 500 index funds to mitigate potential market volatility and capitalize on the strong performance of technology stocks.
See More
AbbVie's Strong Earnings and Skyrizi's Promising Outlook Amid Competition
- Strong Financial Performance: AbbVie's first-quarter earnings exceeded expectations, showcasing robust revenue and profit growth, which indicates the company's strong profitability in a competitive market and is likely to continue attracting investor interest.
- Skyrizi's Market Position Secure: Despite Johnson & Johnson's launch of Icotyde as a competitor, Skyrizi demonstrated a significant efficacy with approximately 70% of patients achieving PASI 90 in clinical trials, far surpassing Icotyde's 50%, thereby solidifying Skyrizi's leadership in psoriasis treatment.
- Sales Forecast Upgrade: AbbVie raised its 2027 sales forecast for Skyrizi and Rinvoq from $27 billion to $31 billion, reflecting strong market demand and confidence in the future growth potential of these two immunosuppressants.
- Consistent Dividend Growth: AbbVie offers a 3.2% dividend yield and has increased its payouts for 54 consecutive years, earning the title of 'Dividend King', which not only boosts investor confidence but also provides a foundation for the company's future financial stability.
See More
NHS to Offer AbbVie's Elahere for Ovarian Cancer Treatment
- New Therapy Introduction: The NHS will start offering AbbVie's ovarian cancer therapy Elahere following a recommendation from NICE, expected to benefit up to 400 patients annually, marking the first new treatment for platinum-resistant ovarian cancer in over two decades.
- Defined Indication: This antibody-drug conjugate will be available for ovarian cancer patients whose disease has progressed after standard platinum-based chemotherapy, particularly those with tumors expressing folate receptor alpha, thus providing a new treatment option for a specific patient group.
- Commercial Agreement Reached: The launch of Elahere will be based on a confidential commercial deal between AbbVie and the NHS, as last year AbbVie indicated it could not launch the drug for NHS patients without securing a reasonable price from NICE, highlighting the importance of drug pricing negotiations.
- Policy Adjustment Impact: NICE has revised its drug value appraisal criteria, committing to increase drug spending in exchange for zero tariffs on British pharmaceuticals and MedTech products as part of a U.K.-U.S. trade deal, paving the way for AbbVie's drug market entry.
See More
Analysis of Healthcare Stock Recovery Opportunities
- AbbVie Outlook: AbbVie's stock has declined 6% this year, yet its immunology drugs Skyrizi and Rinvoq are exceeding expectations, driving revenue and earnings growth, with several new medicines expected to launch over the next five years, enhancing its market competitiveness.
- New Drug Potential: AbbVie's investigational drugs Tavapadon and ABBV-295 are poised for future approvals, with Tavapadon potentially exceeding $1 billion in annual sales, while ABBV-295 offers significant differentiation in the weight management market, bolstering long-term growth prospects.
- Vertex Drug Performance: Vertex Pharmaceuticals' stock is down 5%, but its monopoly in cystic fibrosis will continue to generate stable revenue, with projected new drug revenues reaching $500 million this year, indicating strong potential in product development.
- Clinical Progress and Market Opportunities: Vertex's povetacicept is undergoing accelerated approval, expected by November, which could provide new growth momentum, further solidifying its position in the biopharmaceutical market.
See More
Investment Opportunities in Healthcare Stocks
- AbbVie Stock Performance: AbbVie's stock has declined 6% this year, yet its immunology products Skyrizi and Rinvoq are exceeding expectations, driving revenue and earnings growth, with several new drugs expected to launch in the next five years, particularly Tavapadon for Parkinson's disease, which could exceed $1 billion in annual sales.
- ABBV-295 Potential: AbbVie's investigational weight loss therapy ABBV-295 has shown promising results in clinical trials, and with the growing demand for chronic weight management drugs, it is expected to provide a new revenue stream, further enhancing the competitiveness of its product portfolio.
- Vertex Drug Prospects: Despite Vertex Pharmaceuticals' stock dropping 5%, its cystic fibrosis drugs can still sustain stable revenue, with new drugs Journavx and Casgevy expected to generate at least $500 million in revenue this year, showcasing the company's potential in drug development.
- Clinical Progress and Market Positioning: Vertex is advancing its application for accelerated approval of povetacicept, which, if approved, will become a significant growth driver, and combined with its market performance over the next decade, Vertex remains a top stock to invest in.
See More
Analysis and Comparison of Top Dividend ETFs
- Overview of VYM: The Vanguard High Dividend Yield ETF holds 608 stocks and has delivered an annualized return of 11.5% over the past five years; although it has underperformed the S&P 500 during this period, its diversified portfolio offers lower volatility and better risk management for investors.
- Characteristics of HDV: The iShares Core High Dividend ETF contains only 74 stocks and has achieved an annualized return of 11.4% over the past five years; while its dividend yield of 2.88% is higher than VYM's, its higher concentration may expose investors to greater market risks.
- Investment Strategy Considerations: Despite both ETFs ranking among the top dividend investments, their inability to outperform the S&P 500 over the past five years suggests that investors should consider options with higher growth potential, especially for those seeking capital appreciation.
- Diversification Advantage: VYM's diversified portfolio allows it to effectively mitigate risks in a market environment where technology stocks are heavily weighted, making it suitable for dividend investors looking to avoid concentrated investments in specific sectors.
See More
Wall Street Predicts 14% Upside for S&P 500
- S&P 500 Target Price: Wall Street anticipates a 14% increase in the S&P 500 over the next year, with a target price of 8,698, up from the current level of 7,615, reflecting optimism about economic recovery.
- Healthcare Sector Outlook: Analysts predict that earnings growth in the healthcare sector will slow to 3% by 2026, although it is expected to accelerate to 19% in 2027; however, the current valuation of 27 times earnings may deter investors due to perceived overvaluation.
- Communication Services ETF Performance: The Vanguard Communication Services ETF has returned 152% over the past decade (annualized at 9.6%), with major holdings like Alphabet and Meta, and is projected to see earnings growth of 28% in 2026, indicating strong growth potential.
- Investment Recommendations: Despite the positive outlook for healthcare and communication services, analysts suggest maintaining a larger allocation in S&P 500 index funds to mitigate potential market volatility and capitalize on the strong performance of technology stocks.
See More
AbbVie's Strong Earnings and Skyrizi's Promising Outlook Amid Competition
- Strong Financial Performance: AbbVie's first-quarter earnings exceeded expectations, showcasing robust revenue and profit growth, which indicates the company's strong profitability in a competitive market and is likely to continue attracting investor interest.
- Skyrizi's Market Position Secure: Despite Johnson & Johnson's launch of Icotyde as a competitor, Skyrizi demonstrated a significant efficacy with approximately 70% of patients achieving PASI 90 in clinical trials, far surpassing Icotyde's 50%, thereby solidifying Skyrizi's leadership in psoriasis treatment.
- Sales Forecast Upgrade: AbbVie raised its 2027 sales forecast for Skyrizi and Rinvoq from $27 billion to $31 billion, reflecting strong market demand and confidence in the future growth potential of these two immunosuppressants.
- Consistent Dividend Growth: AbbVie offers a 3.2% dividend yield and has increased its payouts for 54 consecutive years, earning the title of 'Dividend King', which not only boosts investor confidence but also provides a foundation for the company's future financial stability.
See More
